Stockscreener 앱 받기
16.29
0.18%
0.03
시간 외 거래:
16.35
0.06
+0.37%
Viatris Inc 주식(VTRS)의 최신 뉴스
Argus Raises Viatris Price Target to $18 From $15 - marketscreener.com
Why (VTRS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
FDA accepts Viatris' NDA for fast-acting non-opioid pain therapy - MSN
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Tacrolimus Market Research Report 2026: Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2035 - GlobeNewswire Inc.
Viatris Inc. (VTRS) Stock Analysis: Investor Outlook on a Healthcare Giant with an 8.44% Upside Potential - DirectorsTalk Interviews
Assessing Viatris (VTRS) Valuation After FDA Review Acceptance For Fast Acting Non Opioid Meloxicam - Yahoo Finance
Viatris Inc. stock rises Friday, outperforms market - MarketWatch
VTRS News | VIATRIS INC (NASDAQ:VTRS) - ChartMill
What Viatris (VTRS)'s Fast-Acting Pain Drug Filing and Profit Uptick Means For Shareholders - simplywall.st
Viatris Inc.: - marketscreener.com
Viatris (VTRS): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune
Viatris (VTRS) price target increased by 10.47% to 17.48 - MSN
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
VTRS Technical Analysis | Trend, Signals & Chart Patterns | VIATRIS INC (NASDAQ:VTRS) - ChartMill
VTRS Maintains Overweight Rating -- Price Target Raised to $22 - GuruFocus
FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy - Yahoo! Finance Canada
Viatris CFO leaving Canonsburg pharma giant - MSN
Barclays Adjusts Price Target on Viatris to $22 From $17, Maintains Overweight Rating - Moomoo
U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain - Sahm
U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Me - GuruFocus
TrumpRx expands into generic medicines (VTRS:NASDAQ) - Seeking Alpha
Viatris rises as Q1 beat indicates growth momentum - MSN
Viatris' Acute Pain Drug NDA Accepted for Review by FDA - Moomoo
5 Revealing Analyst Questions From Viatris’s Q1 Earnings Call - Yahoo Finance
Here's Why Viatris (VTRS) is a Strong Momentum Stock - Yahoo Finance
U.S. FDA accepts Viatris new drug application for fast-acting meloxicam for the treatment of moderate-to-severe acute pain - marketscreener.com
U.S. FDA Accepts Viatris New Drug Application For Fast-Acting Meloxicam For The Treatment Of Moderate-To-Severe Acute Pain - TradingView
Small Cap Opportunities Trust's Viatris Inc(VTRS) Holding History - GuruFocus
FDA accepts Viatris application for fast-acting meloxicam By Investing.com - Investing.com Nigeria
FDA accepts Viatris application for fast-acting meloxicam - Investing.com
Viatris Inc. (VTRS) Stock Analysis: Exploring a 6.19% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Viatris Inc.Common Stock (NQ: VTRS - FinancialContent
Shareholders that lost money on Viatris Inc.(VTRS) should contac - GuruFocus
Viatris Shareholders Approve Directors, Pay and Auditor - The Globe and Mail
Understanding Momentum Shifts in (VTRS) - Stock Traders Daily
Viatris Inc (VTRS) Stock Down 4.5% but Still Overvalued -- GF Sc - GuruFocus
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Viatris (VTRS) investors elect full board and approve 2025 pay, auditor - Stock Titan
Does Strong Q1 Results And CFO Transition Change The Bull Case For Viatris (VTRS)? - Yahoo Finance
Bacterial Vaginosis Drug Market Will Generate Booming Growth - openPR.com
Biosimilars Market is expected to Hit US$ 99.3 Billion by 2033 | - openPR.com
Fed. Circ. Won't Save Actelion's Suit Over Hypertension Drug - Law360
Earnings call transcript: Viatris Q1 2026 beats EPS forecast, stock rises - Investing.com
Earnings call transcript: Viatris Q1 2026 beats EPS forecast, stock rises By Investing.com - Investing.com South Africa
Viatris Hypertension Drug Doesn’t Copy J&J Patents, Court Says - Bloomberg Law News
Why Viatris (VTRS) is a Top Value Stock for the Long-Term - sharewise.com
0.06%
1.33%
자본화:
|
볼륨(24시간):